VieScope in Patients With an Expected Difficult Airway
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Sep 5, 2021
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Tracheal intubation is required for different surgical procedures for mechanical ventilation and to prevent aspiration of secretions. In patients with an expected difficult airway, tracheal intubation is often performed by videolaryngoscopy (VL). However, this technique has limitations and may fail due to insufficient visualization of the larynx. A new device has been introduced that consists of an illuminated straight plastic tube for laryngoscopy (VSC, Vie Scope, Adroit Surgical, Oklahoma City, OK, USA) that enables for indirect intubation over a stylet.
So far, the VSC has shown promisi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients requiring general anesthesia with transoral tracheal intubation for elective surgery
- • Age ≥ 18
- • Preoperative airway assessment reveals an expected difficult airway (rated by the responsible anesthetist in the Pre-assessment Clinic based on the existing in-house algorithm)
- Exclusion Criteria:
- • Pregnant or breastfeeding woman
- • Confirmed indications for awake fiberoptic intubation especially due to enoral, pharyngeal tumors, abscesses or other processes
- • Planned endotracheal intubation without deep anesthesia or neuromuscular blocking agents (e.g. awake videolaryngoscopy)
- • Required transnasal tracheal intubation (e.g. for surgical reasons)
- • Requirement of special endotracheal tubes such as laser or RAE tubes for surgical reasons
- • Patients at risk for pulmonary aspiration who qualify for rapid sequence induction
- • Loose teeth
- • Denial of consent
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Hamburg, Hh, Germany
Patients applied
Trial Officials
Joern Grensemann, MD
Study Chair
Universitätsklinikum Hamburg-Eppendorf
Martin Petzoldt, MD
Study Chair
Universitätsklinikum Hamburg-Eppendorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials